Source: http://www.google.com/patents/US5935820?dq=5,893,120
Timestamp: 2015-04-19 21:07:13
Document Index: 284441209

Matched Legal Cases: ['application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 08', 'application No. 60']

Patent US5935820 - Polynucleotides encoding vascular endothelial growth factor 2 - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe present invention relates to polynucleotides encoding a novel human protein called Vascular Endothelial Growth Factor 2, or VEGF-2, as well as mature forms, proproteins, and fragments of VEGF-2. Also provided are vectors, host cells, and recombinant methods for producing VEGF-2. The invention further...http://www.google.com/patents/US5935820?utm_source=gb-gplus-sharePatent US5935820 - Polynucleotides encoding vascular endothelial growth factor 2Advanced Patent SearchPublication numberUS5935820 APublication typeGrantApplication numberUS 08/824,996Publication dateAug 10, 1999Filing dateMar 27, 1997Priority dateMar 8, 1994Fee statusLapsedAlso published asCA2184584A1, CA2184584C, CA2414016A1, CN1145636A, CN1267550C, DE69434538D1, DE69434538T2, EP0751992A1, EP0751992A4, EP0751992B1, US7498417, US20020182683, US20040214286, US20090192088, WO1995024473A1Publication number08824996, 824996, US 5935820 A, US 5935820A, US-A-5935820, US5935820 A, US5935820AInventorsJing-Shan Hu, Craig A. Rosen, Liang CaoOriginal AssigneeHuman Genome Science, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (8), Non-Patent Citations (23), Referenced by (83), Classifications (47), Legal Events (7) External Links: USPTO, USPTO Assignment, EspacenetPolynucleotides encoding vascular endothelial growth factor 2
US 5935820 AAbstract
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5073492 *Jan 9, 1987Dec 17, 1991The Johns Hopkins UniversityMixing culture substrate with vascular endothelial cell growth factor, uridine, thymidine and serum-derived factorUS5219739 *Jul 27, 1990Jun 15, 1993Scios Nova Inc.Wound healing agentsUS5326695 *May 15, 1992Jul 5, 1994Ludwig Institute For Cancer ResearchPlatelet derived growth factor agonistsEP0476983A1 *Sep 18, 1991Mar 25, 1992Merck &amp; Co., Inc.Vascular endothelial cell growth factor IIEP0506477A1 *Mar 27, 1992Sep 30, 1992Merck &amp; Co., Inc.Vascular endothelial cell growth factor C subunitWO1997005250A2 *Aug 1, 1996Feb 13, 1997Kari AlitaloReceptor ligand vegf-cWO1997009427A1 *Aug 30, 1996Mar 13, 1997Genentech IncVegf-related proteinWO1997017442A1 *Nov 5, 1996May 15, 1997Immunex CorpFlk-1 binding protein* Cited by examinerNon-Patent CitationsReference1 *Breier, G., et al., Development 114:521 532 (1992).2Breier, G., et al., Development 114:521-532 (1992).3 *Eichmann, A., et al., Development 125(4):743 752 (1998).4Eichmann, A., et al., Development 125(4):743-752 (1998).5 *Ferrara, et al., Journal of Cellular Biochemistry 47:211 218 (1991).6Ferrara, et al., Journal of Cellular Biochemistry 47:211-218 (1991).7 *George et al. Macromolecular Seq. and Syn. Selected Meth & Applic pp. 127 149, 1998.8George et al. Macromolecular Seq. and Syn. Selected Meth & Applic pp. 127-149, 1998.9 *Leung, D.W., et al., Science 246:1306 1309 (1989).10Leung, D.W., et al., Science 246:1306-1309 (1989).11 *Pajusola, K., et al., Cancer Research. 52:5738 5743 (1992).12Pajusola, K., et al., Cancer Research. 52:5738-5743 (1992).13 *Pajusola, K., et al., Oncogene 8:2931 2937 (1993).14Pajusola, K., et al., Oncogene 8:2931-2937 (1993).15 *Tischer, et al., Biochemical and Biophysical Research Communications 165(3):1198 1206 (1989).16Tischer, et al., Biochemical and Biophysical Research Communications 165(3):1198-1206 (1989).17 *U.S. application No. 08/340011, filed Nov. 1994.18 *U.S. application No. 08/510133, filed Aug. 1995.19 *U.S. application No. 08/585895, filed Jan. 1996.20 *U.S. application No. 08/601132, filed Feb. 1996.21 *U.S. application No. 08/671573, filed Jun. 1996.22 *U.S. application No. 08/8554374, filed Nov. 1995.23 *U.S. provisional application No. 60/03491, filed Sep. 1995.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS6130071 *Feb 5, 1997Oct 10, 2000Helsinki University Licensing, Ltd.Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereofUS6221839Aug 1, 1995Apr 24, 2001Helsinki University Licensing Ltd. OyFIt4 ligand and methods of useUS6245530Jan 12, 1996Jun 12, 2001Ludwig Institute For Cancer ResearchReceptor ligandUS6361946Feb 2, 1998Mar 26, 2002Licentia LtdA bone marrow modulating method in mammals by adminstering a polypeptide that binds to at least one endothelial cell surface receptor to modulates myelopoiesisUS6403088Feb 14, 1996Jun 11, 2002Helsinki University Licensing, Ltd.Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)US6506884 *Mar 6, 2000Jan 14, 2003Compugen Ltd.Variant of vascular endothelial growth factorUS6576608May 17, 1999Jun 10, 2003Genentech, Inc.Stimulating tyrosine phosphorylation of Flt4 tyrosine kinase receptor in Flt4-expressing cellUS6608182Jun 6, 1995Aug 19, 2003Human Genome Sciences, Inc.Human vascular endothelial growth factor 2US6645933Jun 28, 1996Nov 11, 2003Helsinki University Licensing Ltd. OyPolypeptide that binds extracellular domain of human Flt4 receptor tyrosine kinase; genetic engineering; endothelial cell growth factors and genesUS6730658Aug 2, 2000May 4, 2004Helsinki University Licensing, Ltd.Stimulation of lymphatic growth with an FLT4 ligandUS6734285Feb 28, 2002May 11, 2004Human Genome Sciences, Inc.Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, inflammation, diabetic retinopathy, rheumatoid arthritis and psoriasisUS6818220Mar 24, 2000Nov 16, 2004Licentia Ltd.Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereofUS6887848Oct 10, 2002May 3, 2005Scios, Inc.Vascular endothelial growth factor variantsUS6958147Oct 26, 1999Oct 25, 2005Licentia LtdUse of VEGF-C to prevent restenosisUS6965010Feb 26, 2001Nov 15, 2005Licentia, Ltd.Polypeptideeptide for use in the treatment of cancer, neovascularization defects, retinopathies, arthritis and psoraisisUS6994989 *Nov 5, 1996Feb 7, 2006Immunex Corp.Fetal liver kinase 1 (flk-1), is a member of the type III subclass of receptor tyrosine kinase (RTK) family; specified amino acid and nucleotide sequences; expression vectors; expression by a host cell; modulators of angiogenesisUS7026462Dec 6, 2001Apr 11, 2006Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS7034105Jan 19, 2001Apr 25, 2006Licentia, Ltd.Endothelial growth factors (Flt4); glycoproteins; tyrosine kinases; immunoglobulinsUS7045133Jan 18, 2001May 16, 2006Ludwig Institute For Cancer ResearchVEGF-D/VEGF-C/VEGF peptidomimetic inhibitorUS7067317Apr 30, 2001Jun 27, 2006Sangamo Biosciences, Inc.Wound healing agentUS7109308Dec 21, 2001Sep 19, 2006Human Genome Sciences, Inc.Inhibiting tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis and psoriasis; diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 proteinUS7115392Apr 23, 2002Oct 3, 2006Human Genome Sciences, Inc.Polynucleotides encoding human vascular endothelial growth factor 2US7125714Jul 23, 2002Oct 24, 2006Licentia Ltd.Progenitor cell materials and methodsUS7125856Apr 11, 2000Oct 24, 2006St. Elizabeth's Medical Center Of Boston, Inc.Angiogenic growth factors for treatment of peripheral neuropathyUS7153827Dec 23, 1998Dec 26, 2006Human Genome Sciences, Inc.Produced by recombinant techniques; stimulating angiogenesis for wound healing and for vascular tissue repairUS7153942Aug 24, 2001Dec 26, 2006Human Genome Sciences, Inc.Polypeptide for use in the treatment of inflammation, rheumatoid arritis, psoriasis, and diabetic retinopathyUS7186688Jun 30, 1998Mar 6, 2007Human Genome Sciences, Inc.Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2US7208582Apr 12, 2002Apr 24, 2007Human Genome Sciences, Inc.Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agentsUS7211240Mar 3, 2003May 1, 2007Bracco International B.V.Multivalent constructs for therapeutic and diagnostic applicationsUS7223724 *Feb 7, 2000May 29, 2007Human Genome Sciences, Inc.Administering a polypeptide attached to a water soluble polymer; treating age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemlc retinopathies, retinal detachment and traumatic retinopathyUS7227005Feb 25, 1999Jun 5, 2007Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7261876Sep 11, 2003Aug 28, 2007Bracco International BvMultimeric proteins for use in the treatment and detection of cell proliferative disordersUS7273751Aug 3, 2001Sep 25, 2007Human Genome Science, Inc.Comprises nucleotide sequences associated with expression vector coding endothelial growth factor for use in diagnosis and treatment of tumor angiogenesis, inflammation, diabetic retinopathy, arthritis and psoriasis; wound healing agentUS7309604Feb 24, 2005Dec 18, 2007Licentia, Ltd.Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS7329740Sep 14, 2005Feb 12, 2008Immunex CorporationFlk-1 binding proteinUS7358085Feb 28, 2006Apr 15, 2008Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7402312Nov 19, 2004Jul 22, 2008Human Genome Sciences, Inc.Immunoglobulin mixture specific to endothelial growth factor for use as tools in treatment and prevention of cell prolifreative disorders; antitumor agentsUS7423125Mar 3, 2004Sep 9, 2008Vegenics LimitedAntibodies to VEGF-CUS7439333Feb 28, 2005Oct 21, 2008Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7498417May 26, 2004Mar 3, 2009Human Genome Sciences, Inc.Comprises nucleotide sequences coding cell growth factors for use in developing modulators for treatment of cell proliferative, arthritic, skin and vision defects; immunotherapyUS7524501Mar 14, 2005Apr 28, 2009Human Genome Sciences, Inc.Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodiesUS7560440Jul 14, 2006Jul 14, 2009Sangamo Bioschiences, Inc.Endothelial growth factors; antiischemic agents; neovascularizationUS7566566Aug 28, 2007Jul 28, 2009Vengenics LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS7576189Aug 26, 2005Aug 18, 2009Human Genome Sciences, Inc.antibodies against such VEGFs, which may be used to inhibit their action, for example, to inhibit the growth of tumors, to treat diabetic retinopathy, rheumatoid arthritis and psoriasisUS7605140Apr 26, 2005Oct 20, 2009Sangamo Biosciences, Inc.Endothelial growth factors; antiischemic agents; neovascularizationUS7611711Jan 15, 2002Nov 3, 2009Vegenics LimitedVEGFR-3 inhibitor materials and methodsUS7629145Jun 29, 2006Dec 8, 2009Genentech, Inc.Expression vector comprising nucleotide sequences coding endothelial growth factor protein for use in prevention and treatment of cell proliferative and eye disordersUS7666979Aug 11, 2004Feb 23, 2010Bracco International B.V.Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the sameUS7709270Oct 30, 2007May 4, 2010Vegenics Ltd.Using platelete derived growth factor as tool in detection of modulators for prevention and treatment of cell proliferative disordersUS7727761Mar 3, 2004Jun 1, 2010Vegenics LimitedVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS7732196Dec 6, 2007Jun 8, 2010Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7794693Dec 8, 2006Sep 14, 2010Bracco International B.V.Targeting vector-phospholipid conjugatesUS7794756Oct 30, 2007Sep 14, 2010Vegenics LimitedMethods of using antibodies to VEGF-CUS7795209Oct 31, 2007Sep 14, 2010Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7807412Oct 30, 2007Oct 5, 2010Vegenies LimitedUsing platelete derived growth fator as tool in detection of modulators for prevention and treatment of cell proliferative disordersUS7829536Feb 5, 2009Nov 9, 2010Vegenics Limitedadministering to a patient with lymphedema a therapeutically effective amount of a vascular endothelial growth factor D (VEGF-D) protein at the site of edema, that binds and stimulates wild-type VEGFR-3; genetic disorders; screeningUS7850963Apr 3, 2007Dec 14, 2010Human Genome Sciences, Inc.Vascular endothelial growth factor 2US7854919Jan 19, 2007Dec 21, 2010Bracco, Suisse SAMultivalent constructs for therapeutic and diagnostic applicationsUS7893022Oct 31, 2007Feb 22, 2011Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS7902149Apr 10, 2009Mar 8, 2011Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS7910088Mar 21, 2007Mar 22, 2011Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS7985402Dec 11, 2007Jul 26, 2011Bracco Suisse SaUltrasound contrast agent of peptide monomers; peptide vectors having high KDR binding affinity; gas filled microvesicle containing a fluorinated gas and a phospholipidUS8012946Jan 9, 2008Sep 6, 2011Sangamo Biosciences, Inc.Anti-angiogenic methods and compositionsUS8044175Jan 30, 2008Oct 25, 2011Dyax Corp.Peptides that specifically bind HGF receptor (CMET) and uses thereofUS8071564Sep 3, 2009Dec 6, 2011Sangamo Biosciences, Inc.Regulation of angiogenesis with zinc finger proteinsUS8206708Apr 28, 2011Jun 26, 2012Human Genome Sciences, Inc.Vascular endothelial growth factor 2US8216569Oct 31, 2007Jul 10, 2012Human Genome Sciences, Inc.Vascular endothelial growth factor 2US8278098Jan 28, 2011Oct 2, 2012Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteinsUS8282931Sep 10, 2010Oct 9, 2012Vegenics Pty LimitedVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS8357669Sep 23, 2011Jan 22, 2013Vegenics Pty LimitedMethod of treatment for lymphedema comprising administering a polynucleotide encoding VEGF-DUS8455453Feb 24, 2005Jun 4, 2013Vegenics Pty LtdUse of VEGF-D gene to prevent restenosisUS8551450May 19, 2010Oct 8, 2013Philippe BussatTargeting vector-phospholipid conjugatesUS8623822Oct 5, 2010Jan 7, 2014Bracco Suisse SaKDR and VEGF/KDR binding peptides and their use in diagnosis and therapyUS8632753Dec 20, 2010Jan 21, 2014Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS8637262Oct 5, 2012Jan 28, 2014Vegenics Pty LimitedVascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereofUS8642010Jun 8, 2009Feb 4, 2014Dyax Corp.KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyUS8663603Sep 23, 2010Mar 4, 2014Bracco Suisse SaMultivalent constructs for therapeutic and diagnostic applicationsUS8784809Jan 24, 2013Jul 22, 2014Human Genome Sciences, Inc.Vascular endothelial growth factor 2US8940695Jan 6, 2006Jan 27, 2015Vegenics Pty LimitedFlt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapyEP2277528A2Apr 12, 2001Jan 26, 2011Vlaams Interuniversitair Instituut voor BiotechnologieUse of VEGF and homologues to treat neuron disordersEP2295070A1Apr 12, 2001Mar 16, 2011Vlaams Interuniversitair Instituut voor BiotechnologieUse of VEGF and homologues to treat neuron disordersEP2314614A1Feb 28, 2006Apr 27, 2011Sangamo BioSciences, Inc.Anti-angiogenic methods and compositionsWO2002011769A1 *Aug 3, 2001Feb 14, 2002Timothy A ColemanVascular endothelial growth factor 2* Cited by examinerClassifications U.S. Classification435/69.4, 435/243, 435/70.1, 530/399, 536/23.4, 536/23.51, 435/320.1, 435/325International ClassificationC07K16/24, A61P17/02, A61K48/00, C12N15/12, C12N15/63, C07H21/00, A61K39/235, C07K16/18, A61P17/06, A61K49/00, A61K39/00, C07H21/04, A61P9/14, C07K14/52, A61P35/00, C12P21/02, A61P29/00, A61K39/395, A61K38/27, C12N1/21, A61P3/10, A61P27/02, C12N1/19, C12N15/18, A61K38/55, A61P9/00, A61K38/00, A61P43/00, C07K14/475, C12N15/09, C12P21/08, C07K14/485, G01N33/53, C12N5/10Cooperative ClassificationA61K39/00, A61K38/00, C07K2319/00, C07K14/52European ClassificationC07K14/52Legal EventsDateCodeEventDescriptionSep 27, 2011FPExpired due to failure to pay maintenance feeEffective date: 20110810Aug 10, 2011LAPSLapse for failure to pay maintenance feesMar 14, 2011REMIMaintenance fee reminder mailedFeb 12, 2007FPAYFee paymentYear of fee payment: 8Feb 7, 2003FPAYFee paymentYear of fee payment: 4Dec 26, 2000CCCertificate of correctionDec 11, 1998ASAssignmentOwner name: HUMAN GENOME SCIENCES, INC., MARYLANDFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HU, JING-SHAN;ROSEN, CRAIG A.;CAO, LIANG;REEL/FRAME:009914/0313;SIGNING DATES FROM 19980724 TO 19980727RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services